UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | September 13, 2024 5:00 P.M. |
Form: | S-1 | ||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | September 13, 2024 5:00 P.M. |
Form: | S-1 | ||||||
|
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/16/2024 | $20.00 | Buy | ROTH MKM |
Strategic Appointment Enhances GeoVax's Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of Teresa Lambe, PhD, OBE, FMedSci to its Scientific Advisory Board. Professor Lambe is the Calleva Head of Vaccine Immunology at the Oxford Vaccine Group within the University of Oxford and a Principal Investigator at the Pandemic Sciences Institute (PSI). She served as one of the Principal Investigators who oversaw the Oxford/AstraZeneca vaccine program; she co-designed the vacci
Strengthening GeoVax's Team Advancing Gedeptin® Clinical Program ATLANTA, GA, Jan. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced the appointment of J. Marc Pipas, M.D., to serve as the Company's Executive Medical Director, Oncology. Kelly McKee, M.D., MPH, GeoVax Chief Medical Officer, commented, "Dr. Pipas' addition to our team represents an important step forward in the strengthening of GeoVax's organizational and operational resources to support advancement of our principal oncology asset, Gedeptin®, through clinical development
First Woman President and CEO of MSM and Internationally Recognized Health Equity Advocate Joins in GeoVax Special Advisory Role ATLANTA, GA, Dec. 20, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the appointment of Valerie Montgomery Rice, MD, FACOG, Morehouse School of Medicine President and CEO, as Special Advisor to the Chairman/CEO and Board of Directors of GeoVax. Dr. Montgomery Rice brings GeoVax exceptional expertise and highly recognized experience at the highest levels of healthcare leadership, patient care, biomedical resear
Awarded BARDA Project NextGen (PNG) contract to advance GeoVax's multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG award represents greater than $350 million in support of PNG GEO-CM04S1 clinical trial, including direct funding of CRO partner Allucent Multiple planned data readouts for GEO-CM04S1 throughout second half of 2024;Gedeptin® to advance into expanded Phase 2 clinical trial with activation in the first half of 2025 Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developin
GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, July 30, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it will report second quarter 2024 financial results on Tuesday, August 6, 2024, after the close of U.S. markets. Following the release, management will host a live conference call and webcast, including Q&A, at 4:30 p.m. ET to provide a corporate update and discuss financial results. Conference Call DetailsDomestic: (800) 715-9871International: +1 (646) 307-1963Conference ID: 3852178Webcast: https://edge.media-server.com/mmc
Progress across the pipeline in multiple clinical trials, includingPhase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, andmulticenter Phase 1/2 study of Gedeptin®, targeting advanced head and neck cancer Catalyst-rich 2024 with data readouts planned throughout the year Company to host conference call and webcast today at 4:30 p.m. ET ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023. "2023 marked an
8-K - GeoVax Labs, Inc. (0000832489) (Filer)
EFFECT - GeoVax Labs, Inc. (0000832489) (Filer)
EFFECT - GeoVax Labs, Inc. (0000832489) (Filer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
4 - GeoVax Labs, Inc. (0000832489) (Issuer)
ROTH MKM initiated coverage of GeoVax Labs with a rating of Buy and set a new price target of $20.00
SC 13G - GeoVax Labs, Inc. (0000832489) (Subject)
SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)
SC 13G/A - GeoVax Labs, Inc. (0000832489) (Subject)
ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that its Chairman and CEO, David Dodd, will present at two upcoming investor events: H.C. Wainwright 26th Annual Global Investment Conference Speaker: David Dodd, Chairman & CEO Date/Time: September 9, 2024 at 7:00 a.m. ET Location: Lotte New York Palace Hotel, New York, NY Webcast Link: H.C. Wainwright Webcast Title: GeoVax Corporate Update Senior GeoVax management will host one-on-one meetings with registered attendees. If interested in meeting with management at
ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (NASDAQ:GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancer and infectious diseases, today announced that it has entered into a definitive securities purchase agreement with a certain institutional investor for the purchase and sale of 975,610 shares of the Company's common stock (or common stock equivalents) at a price of $5.125 per share in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue to the investor warrants to purchase up to 975,610 shares of common stock. The warrants have
Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for Control, Treatment, and Prevention ATLANTA, GA, Aug. 21, 2024 (GLOBE NEWSWIRE) -- GeoVax Lab, Inc. (NASDAQ:GOVX) ("GeoVax Labs" or the "Company"), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that David Dodd, CEO of GeoVax Labs, will present at Tribe Public's Webinar Presentation and Q&A Event titled "Now Is Not the Time to Monkey(pox) Around." The Event is scheduled to begin at 8:00am PT / 11:00am ET on Friday, August 23, 2024. To register to join the complimentary event, please visit the Tribe Public LLC w
EF Hutton analyst Jason Kolbert initiates coverage on Geovax Labs (NASDAQ:GOVX) with a Buy rating and announces Price Target of $18.
SILO: 143% | Silo Pharma Obtains Exclusive Global License To Develop, Manufacture, And Commercialize Its Alzheimer's Drug GOVX: 35% | Roth MKM Initiates Coverage On Geovax Labs with Buy Rating, Announces Price Target of $20 CFB: -12% | CrossFirst Bankshares shares are trading lower. The company reported Q2 financial results.